Blood Glucose Management
Newly diagnosed type 2 DM patients without standard antidiabetic
treatments before the onset of IMHB were identified (diagnostic criteria
of type 2 DM included: hemoglobin A1c [HbA1c] ≥6.5%, fasting plasma
glucose ≥126 mg/dL, and 2 hour plasma glucose≥200 mg/dL). The insulin
therapy for these patients included the insulin pump with and without
long-acting and short-acting subcutaneous insulin to achieve efficient
rapid glycemic control during the acute phase (with the help of a
physician, D.J. ). The target blood glucose level included
proper blood glucose levels of fasting and premeal states (80-130 mg/dL)
and the postprandial state (less than 180 mg/dL) [7] . After
achieving target glucose control, type 2 DM patients were transitioned
to scheduled subcutaneous insulin therapy combined with the admission of
oral antidiabetic medication drugs. After TEVAR or open surgery,
patients with persistently elevated serum glucose (> 180
mg/dL) received continuous intravenous insulin perfusion to maintain
serum glucose < 180 mg/dL during their stay in the intensive
care unit and then were transitioned to their preoperative scheduled
insulin therapy combined with oral antidiabetic drugs [7] .